The CFMe2-substituent is a close analogue of the CF3-group. The CF3 for CFMe2 replacement in model compounds mostly does not affect key physicochemical properties: water solubility, lipophilicity, and metabolic stability. Analogous replacement in the anticancer drug Enasidenib, however, provides a biologically active analogue with improved solubility and reduced lipophilicity.